Acadesine during fluid resuscitation from shock and abdominal sepsis

Critical Care Medicine

Volumn 27, Issue 3, 1999, Pages 565-575

  Melton, Sherry M ^a   Moomey Jr , Charles B ^a   Ragsdale, D Nicholas ^a   Trenthem, Lisa L ^a   Croce, Martin A ^a   Fabian, Timothy C ^a   Proctor, Kenneth G ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Acadesine; Adenosine; Cecal ligation and puncture; Hemorrhagic shock; Laser Doppler; Sepsis; Swine; Trauma; Tumor necrosis factor

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENOSINE; GLUCOSE; LACTIC ACID; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BACTERIAL COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLUID THERAPY; GLUCOSE BLOOD LEVEL; HEART INDEX; HEMODYNAMICS; HEMORRHAGIC SHOCK; INTESTINE BLOOD FLOW; LACTATE BLOOD LEVEL; MALE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; SEPSIS; SWINE; SYSTEMIC VASCULAR RESISTANCE; TISSUE PERFUSION;

EID: 0032907845     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199903000-00037     Document Type: Article

References (46)

1. 1. Mullane K: Acadesine: The prototype adenosine regulating agent for reducing myocardial ischaemic injury. Cardiovasc Res 1993; 27:43-47
2. 2. Cronstein BN: Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994; 76:5-13
3. 3. Ely SW, Berne RM: Protective effects of adenosine in myocardial ischemia. Circulation 1992; 85:893-904
4. 4. Engler RL: Harnessing nature's own cardiac defense mechanism with acadesine, an adenosine regulating agent: importance of the endothelium. J Card Surg 1994; 9(Suppl 3):482-492
5. 5. Mullane K, Bullough D: Harnessing an endogenous cardioprotective mechanism: Cellular sources and sites of action of adenosine. J Mol Cell Cardiol 1995; 27:1041-1054
6. 6. Multicenter Study of Perioperative Ischemia (McSPI) Research Group: Effects of acadesine on the incidence of myocardial infarction and adverse cardiac outcomes after coronary artery bypass graft surgery. Anesthesiology 1995; 83:658-673
7. 7. Demeyere RH, Van Kerrebroeck CJ, Flameng WJ: Cardioprotective effects of acadesine in patients with unstable angina undergoing aortocoronary bypass surgery. Abstr. Circulation 1994; 90(Suppl 4 pt 2); I-370
8. 8. Leung JM, Stanley T III, Mathew J, et al: An initial multicenter, randomized controlled trial on the safety and efficacy of acadesine in patients undergoing coronary artery bypass graft surgery. SPI Research Group. Anesth Analg 1994; 78:420-434
9. 9. Menasche P, Jamieson WR, Flameng W, Davies MK: Acadesine: A new drug that may improve myocardial protection in coronary artery bypass grafting. Results of the first international multicenter study. Multinational Acadesine Study Group. J Thorac Cardiovasc Surg 1995; 110(Suppl 4 Pt 1): 1096-1106
10. 10. Mangano DT: Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. JAMA 1997; 277:325-332
11. 11. Kaminski PM, Proctor KG: Actions of adenosine on nitro blue tetrazolium deposition and surface pH during intestinal reperfusion injury. Circ Res 1990; 66:1713-1719
12. 12. Kaminski PM, Proctor KG: Extracellular and Intracellular Actions of Adenosine and Related Compounds in the Reperfused Rat Intestine. Circ Res 1992; 71:720-731
13. 13. Rosengren S, Arfors KE, Proctor KG: Potentiation of leukotriene B4-mediated inflammatory response by the adenosine antagonist, 8-phenyl theophylline. Int J Microcirc Clin Exp 1991; 10:345-357
14. 14. Spiers JP, Fabian TC, Kudsk KA, Proctor KG: Resuscitation of hemorrhagic shock with hypertonic saline/dextran or lactated Ringer's supplemented with AICA riboside. Circ Shock 1993; 40:29-36
15. 15. Fabian TC, Fabian MJ, Yockey JM, Proctor KG: Acadesine and lipopolysaccharide-evoked pulmonary dysfunction after resuscitation from traumatic shock. Surgery 1996; 119:302-315
16. 16. Bone RC, Balk RA, Fein AM, et al: The E5 sepsis study group: A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995; 23:994-1006
17. 17. Cohen J, Carlet J; INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24:1431-1440
18. 18. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24:733-742
19. 19. Dellinger RP: Post hoc analyses in sepsis trials: a formula for disappointment? Crit Care Med 1996; 24:727-729
20. 20. Fink MP: Another negative clinical trial of a new agent for the treatment of sepsis: Rethinking the process of developing adjuvant treatments for serious infections. Crit Care Med 1996; 23:989-991
21. 21. Piper RD, Cook DJ, Bone RC, Sibbald WJ: Introducing Critical Appraisal to studies of animal models investigating novel therapies in sepsis. Crit Care Med 1996; 24:2059-2070
22. 22. Lyden SP, Patton JH Jr, Ragsdale DN, et al: Transient inhibition of CD18-dependent leukocyte functions after hemorrhage and polymicrobial sepsis. Surgery 1998; 126:679-691
23. 23. Patton JH Jr, Lyden SP, Ragsdale DN, et al: G-CSF in hemorrhagic shock and intra-abdominal sepsis: improved host defense without generalized neutrophil mediated injury. J Trauma, 1998; 44:750-758
24. 24. Fabian TC, Croce MA, Fabian MJ, et al: Reduced tumor necrosis factor production in endotoxin-spiked whole blood after trauma: experimental results and clinical correlation. Surgery 1995; 118:63-72
25. 25. Barroso-Aranda J, Schmid-Schonbein GW, Zweifach BW, et al: Granulocytes and no-reflow phenomenon in irreversible hemorrhagic shock. Circ Res 1988; 63:437-447
26. 26. Bullough DA, Magill MJ, Firestein GS, et al: Adenosine activates A2 receptors to inhibit neutrophil adhesion and injury to isolated cardiac myocytes. J Immunol 1995; 155: 2579-2586
27. 27. Gruber HE, Hoffer ME, McAllister DR, et al: Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury. Circulation 1989; 80:1400-1411
28. 28. Bullough DA, Zhang C, Montag A, et al: Adenosine-mediated inhibition of platelet aggregation by acadesine. A novel antithrombotic mechanism in vitro and in vivo. J Clin Invest 1994; 94:1524-1532
29. 29. Dietrich WD, Miller LP, Prado R, et al: Acadesine reduces indium-labeled platelet deposition after photothrombosis of the common carotid artery in rats. Stroke 1995; 26:111-116
30. 30. Young MA, Henry C, Wong S, et al: Acadesine reduces the frequency of coronary artery reocclusion following rt-PA induced thrombolysis in the dog. Thromb Haemost 1995; 74:1348-1352
31. 31. Akkan AG, Malaisse WJ: Insulinotropic action of AICA riboside. I. Insulin release by isolated islets and the perfused pancreas. Diabetes Res 1994; 25:13-23
32. 32. Schoenberg MH, Poch B, Moch D, et al: Effect of acadesine treatment on postischemic damage to small intestine. Am J Physiol 1995; 269(5 Pt 2):H1752-1759
33. 33. Sajjadi FG, Takabayashi K, Foster AC, et al: Inhibition of TNF-α expression by adenosine: role of A3 adenosine receptors. J Immunol 1996; 156:3435-3442
34. 34. Bullough DA, Magill MJ, Mullane KM, et al: Carbohydrate-and CD18-dependent neutrophil adhesion to cardiac myocytes: Effects of adenosine. Cardiovasc Res 1996; 32:328-334
35. 35. Firestein GS, Boyle D, Bullough DA, et al: Protective effect of an adenosine kinase inhibitor in septic shock. J Immunol 1994; 152:5853-5859
36. 36. Mathew JP, Rinder CS, Tracey JB, et al: Acadesine inhibits neutrophil CD11b up-regulation in vitro and during in vivo cardiopulmonary bypass. J Thorac Cardiovasc Surg 1995; 109:448-456
37. 37. Galinanes M, Bullough D, Mullane KM, et al: Sustained protection by acadesine against ischemia-and reperfusion-induced injury. Studies in the transplanted rat heart. Circulation 1992; 86:589-597
38. 38. Galinanes M, Mullane KM, Bullough D, et al: Acadesine and myocardial protection. Studies of time of administration and dose-response relations in the rat. Circulation 1992; 86:598-608
39. 39. Tsuchida A, Liu GS, Mullane K, et al: Acadesine lowers temporal threshold for the myocardial infarct size limiting effect of preconditioning. Cardiovasc Res 1993; 27:116-120
40. 40. Tsuchida A, Yang XM, Burckhartt B, et al: Acadesine extends the window of protection afforded by ischaemic preconditioning. Cardiovasc Res 1994; 28:379-383
41. 41. Burckhartt B, Yang XM, Tsuchida A, et al: Acadesine extends the window of protection afforded by ischaemic preconditioning in conscious rabbits. Cardiovasc Res 1995; 29:653-657
42. 42. Zhao ZQ, Williams MW, Sato H, et al: Acadesine reduces myocardial infarct size by an adenosine mediated mechanism. Cardiovasc Res 1995; 29:495-505
43. 43. Hori M, Kitakaze M, Takashima S, et al: AICA riboside improves myocardial ischemia in coronary microembolization in dogs. Am J Physiol 1994; 267(4 Pt 2):H1483-1495
44. 44. Bolling SF, Groh MA, Mattson AM, et al: Acadesine (AICA-riboside) improves postischemic cardiac recovery. Ann Thorac Surg 1992; 54:93-98
45. 45. Vinten-Johansen J, Nakanishi K, Zhao ZQ, et al: Acadesine improves surgical myocardial protection with blood cardioplegia in ischemically injured canine hearts. Circulation 1993; 88(Suppl 5 Pt 2):II350-II358
46. 46. Sellke FW, Friedman M, Wang SY, et al: Adenosine and AICA-riboside fail to enhance microvascular endothelial preservation. Ann Thorac Surg 1994; 58:200-206